Klopidogrel-Teva of the tab. of p/o of 75 mg No. 90

Klopidogrel-Tev's tablets are applied at indications which are provided below.

Prevention of manifestations of an aterotromboz at adults:

• at the patients who had a myocardial infarction (an initiation of treatment - in several days, but not later than in 35 days after emergence), an ischemic stroke (an initiation of treatment - in 7 days, but not later than in 6 months after emergence) or for which the disease of peripheral arteries is diagnosed (damage of arteries and aterotromboz vessels of the lower extremities);
• at patients with a sharp coronary syndrome:
  • with a sharp coronary syndrome without raising of a segment of ST (unstable stenocardia or a myocardial infarction without tooth Q), including at patients to whom the stent was established during performing transdermal coronary angioplasty, in a combination with acetylsalicylic acid (ASK);
  • with an acute myocardial infarction with raising of a segment of ST in a combination with acetylsalicylic acid (at the patients receiving standard medicament treatment and to which thrombolytic therapy is shown).

Prevention of aterotrombotichesky and thromboembolic events at fibrillation of auricles. Klopidogrel in a combination with ASK is shown to adult patients with fibrillation of auricles which have at least one risk factor of emergence of vascular events to which treatment by the antagonists of vitamin K (AVK) is contraindicated and which have low risk of developing of bleedings, for prevention of aterotrombotichesky and thromboembolic events, including a stroke.

Structure

Active ingredient: klopidogret;

1 tablet contains klopidogrelya bisulphate 97.86 mg that is equivalent to 75 mg klopidogrelya;

Excipients: lactose, cellulose microcrystalline, krospovidon, glycerin dibegenat, talc;

Cover: Opadry II 85G34669 pink (polyvinyl alcohol, talc, macrogoal 3350, lecithin, titan dioxide (E 171), ferrous oxide red (E172)).

Contraindication

• hypersensitivity to active ingredient or to any component of drug;
• heavy liver failure;
• acute bleeding (for example ulcer or intracraneal hemorrhage).

by

on 75 mg of 1 times a day irrespective of meal.

treatment klopidogrely to begin with

At patients with a sharp coronary syndrome without raising of a segment of ST (unstable stenocardia or a myocardial infarction without Q tooth on the ECG) with a single load dose 300 mg, and then to continue in a dose 75 mg of 1 times a day (with acetylsalicylic acid (ASK) in a dose of 75-325 mg a day). As use of higher doses of ASK increases risk of bleeding, it is not recommended to exceed a dose of ASK of 100 mg.

Optimum duration of treatment is formally not established to

. Results of clinical trials testify in favor of use of medicament up to 12 months, and the maximum effect was observed in 3 months of treatment.

klopidogret

At patients with an acute myocardial infarction with raising of a segment of ST to appoint 75 mg once a day, to begin with a single load dose 300 mg in a combination with ASK, using thrombolytic medicaments or without them. To begin treatment of patients aged from 75 years without load dose klopidogrelya. Combination therapy should be begun as soon as possible after emergence of symptoms and to continue at least 4 weeks. The advantage of a combination klopidogrelya with ASK in this disease was not studied more than 4 weeks.

to Patients with fibrillation of auricles klopidogrel to apply 75 mg in a single dose. Together with klopidogrely it is necessary to begin and continue use of ASK (in a dose of 75-100 mg a day).

Feature of use

Pregnant

due to the lack of clinical data on use klopidogrelya during pregnancy it is undesirable to p to appoint medicament to pregnant women (precautionary measure).

whether it is removed klopidogrel in breast milk. In researches on animals it was shown that it is removed in breast milk therefore during medicament treatment of Klopidogrel-Tev the feeding by a breast should be stopped.

Children

Klopidogrel should not be applied to children as there are no data on efficiency of medicament for this age category of patients.

Drivers

Klopidogrel does not influence or has insignificant impact on speed of response at control of motor transport or work with other mechanisms.

Overdose

At overdose increase in a bleeding time with the subsequent complications. In case of developing of bleeding the symptomatic treatment is recommended.

. In need of immediate correction of the extended bleeding time klopidogrelya it can be terminated by transfusion of platelet concentrate.

Side effects

Bleeding was the most widespread side reaction which was observed both in clinical trials, and during the post-marketing period during which it most often arose in the first month of treatment.

to Store

at a temperature not above 25 °C. To store out of children's reach.

Expiration date - 3 years.